A new blood test developed by experts at Washington University and Lund University could change the way Alzheimer’s is diagnosed and treated, identifying disease progression and guiding personalized care.
A groundbreaking study reveals that a biologic drug may delay Alzheimer's symptoms in individuals with genetic predispositions. With promising results, researchers emphasize the importance of continued funding for further investigation.
Study shows that new Alzheimer's drugs lecanemab and donanemab can significantly extend the period of independent living for patients with early-stage Alzheimer's disease, highlighting potential benefits and risks.
